Changes in quality of life following cognitive-behavioral group therapy for panic disorder

European Psychiatry

Volumn 25, Issue 1, 2010, Pages 8-14

  Rufer, M ^a   Albrecht, R ^b   Schmidt, O ^b   Zaum, J ^b   Schnyder, U ^a   Hand, I ^b   Mueller Pfeiffer, C ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Center of Education and Research   (Switzerland)

Author keywords

Behavior therapy; Cognitive therapy; Panic disorder; Quality of life; Treatment outcome

Indexed keywords

ADULT; AGORAPHOBIA; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GROUP THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PANIC; PRIORITY JOURNAL; PSYCHOTHERAPIST; QUALITY OF LIFE; SAMPLE SIZE; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE; WELLBEING;

ADULT; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; PANIC DISORDER; PSYCHOTHERAPY, GROUP; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 73849138669     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.05.003     Document Type: Article

References (55)

1. Ackenheil M., Stotz G., Dietz-Bauer R., and Vossen A. Mini International Interview - German Version 5.0.0 (1999), Psychiatrische Universitätsklinik München, Germany
2. Alsleben H., Weiss A., and Rufer M. Psychoedukation Angst- und Panikstörungen. Manual zur Leitung von Patienten- und Angehörigengruppen (2004), Elsevier Urban & Fischer, München
3. Arntz A. Cognitive therapy versus interoceptive exposure as treatment of panic disorder without agoraphobia. Behav Res Ther 40 (2002) 325-341
4. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10 (1995) 73-81
5. Bandelow B. Panik- und Agoraphobia-Skala (PAS) (1997), Hogrefe, Göttingen
6. Bandelow B., Broocks A., Pekrun G., George A., Meyer T., Pralle L., et al. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry 33 (2000) 174-181
7. Bandelow B., Brunner E., Broocks A., Beinroth D., Hajak G., Pralle L., et al. The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res 77 (1998) 43-49
8. Bandelow B., Stein D.J., Dolberg O.T., Andersen H.F., and Baldwin D.S. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40 (2007) 152-156
9. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
10. Bullinger M., and Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand (1998), Hogrefe, Göttingen
11. Candilis P.J., McLean R.Y., Otto M.W., Manfro G.G., Worthington III J.J., Penava S.J., et al. Quality of life in patients with panic disorder. J Nerv Ment Dis 187 (1999) 429-434
12. Carrera M., Herran A., Ayuso-Mateos J.L., Sierra-Biddle D., Ramirez M.L., Ayestaran A., et al. Quality of life in early phases of panic disorder: predictive factors. J Affect Disord 94 (2006) 127-134
13. Cohen D. Statistical Power Analysis for Behavioral Sciences (1988), Erlbaum, Hillsdale
14. Dow M.G., Kenardy J.A., Johnston D.W., Newman M.G., Taylor C.B., and Thomson A. Prognostic indices with brief and standard CBT for panic disorder: I. Predictors of outcome. Psychol Med 37 (2007) 1493-1502
15. Dow M.G., Kenardy J.A., Johnston D.W., Newman M.G., Taylor C.B., and Thomson A. Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol Med 37 (2007) 1503-1509
16. Eaton W.W., Kessler R.C., Wittchen H.U., and Magee W.J. Panic and panic disorder in the United States. Am J Psychiatry 151 (1994) 413-420
17. Ettigi P., Meyerhoff A.S., Chirban J.T., Jacobs R.J., and Wilson R.R. The quality of life and employment in panic disorder. J Nerv Ment Dis 185 (1997) 368-372
18. Fava G.A. Well-being therapy: conceptual and technical issues. Psychother Psychosom 68 (1999) 171-179
19. Fava G.A., Rafanelli C., Ottolini F., Ruini C., Cazzaro M., and Grandi S. Psychological well-being and residual symptoms in remitted patients with panic disorder and agoraphobia. J Affect Disord 65 (2001) 185-190
20. Fava G.A., Rafanelli C., Tossani E., and Grandi S. Agoraphobia is a disease: a tribute to Sir Martin Roth. Psychother Psychosom 77 (2008) 133-138
21. Fava G.A., Ruini C., Rafanelli C., Finos L., Salmaso L., Mangelli L., et al. Well-being therapy of generalized anxiety disorder. Psychother Psychosom 74 (2005) 26-30
22. Furukawa T.A., Watanabe N., and Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry 188 (2006) 305-312
23. Fyer A.J., Katon W., Hollifield M., Rassnick H., Mannuzza S., Chapman T., et al. The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety 2 (1996) 157-166
24. Heldt E., Blaya C., Isolan L., Kipper L., Teruchkin B., Otto M.W., et al. Quality of life and treatment outcome in panic disorder: cognitive behavior group therapy effects in patients refractory to medication treatment. Psychother Psychosom 75 (2006) 183-186
25. Hoehn-Saric R., McLeod D.R., and Hipsley P.A. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13 (1993) 321-326
26. Hollifield M., Katon W., Skipper B., Chapman T., Ballenger J.C., Mannuzza S., et al. Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry 154 (1997) 766-772
27. Jacobs R.J., Davidson J.R., Gupta S., and Meyerhoff A.S. The effects of clonazepam on quality of life and work productivity in panic disorder. Am J Manag Care 3 (1997) 1187-1196
28. Katon W., Hollifield M., Chapman T., Mannuzza S., Ballenger J., and Fyer A. Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res 29 (1995) 121-131
29. Kenardy J.A., Dow M.G., Johnston D.W., Newman M.G., Thomson A., and Taylor C.B. A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: an international multicenter trial. J Consult Clin Psychol 71 (2003) 1068-1075
30. Kiropoulos L.A., Klein B., Austin D.W., Gilson K., Pier C., Mitchell J., et al. Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT?. J Anxiety Disord 22 (2008) 1273-1284
31. Lecrubier Y., and Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95 (1997) 153-160
32. Markowitz J.S., Weissman M.M., Ouellette R., Lish J.D., and Klerman G.L. Quality of life in panic disorder. Arch Gen Psychiatry 46 (1989) 984-992
33. Mavissakalian M.R., Perel J.M., Talbott-Green M., and Sloan C. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 43 (1998) 848-854
34. McHorney C.A., Ware Jr. J.E., and Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31 (1993) 247-263
35. Mendlowicz M.V., and Stein M.B. Quality of life in individuals with anxiety disorders. Am J Psychiatry 157 (2000) 669-682
36. Michelson D., Lydiard R.B., Pollack M.H., Tamura R.N., Hoog S.L., Tepner R., et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155 (1998) 1570-1577
37. Moritz S., Rufer M., Fricke S., Karow A., Morfeld M., Jelinek L., et al. Quality of life in obsessive-compulsive disorder before and after treatment. Compr Psychiatry 46 (2005) 453-459
38. Mortimer D., and Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 28 (2008) 66-89
39. Olatunji B.O., Cisler J.M., and Tolin D.F. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev 27 (2007) 572-581
40. Pohl R.B., Wolkow R.M., and Clary C.M. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155 (1998) 1189-1195
41. Pollack M.H., Otto M.W., Worthington J.J., Manfro G.G., and Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55 (1998) 1010-1016
42. Rapaport M.H., Pollack M., Wolkow R., Mardekian J., and Clary C. Is placebo response the same as drug response in panic disorder?. Am J Psychiatry 157 (2000) 1014-1016
43. Roy-Byrne P.P., Craske M.G., and Stein M.B. Panic disorder. Lancet 368 (2006) 1023-1032
44. Ruhmland M., and Margraf J. Efficacy of psychological treatments for panic and agoraphobia. Verhaltenstherapie 11 (2001) 41-53
45. Schonfeld W.H., Verboncoeur C.J., Fifer S.K., Lipschutz R.C., Lubeck D.P., and Buesching D.P. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord 43 (1997) 105-119
46. Shao J., and Zhong B. Last observation carry-forward and last observation analysis. Stat Med 22 (2003) 2429-2441
47. Sheehan D.V. The anxiety disease (1983), Charles Scribner's Sons, New York
48. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (1998) 22-33
49. Telch M.J., Schmidt N.B., Jaimez T.L., Jacquin K.M., and Harrington P.J. Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. J Consult Clin Psychol 63 (1995) 823-830
50. Tsai C., Bayliss M.S., and Ware J.E. SF-36 Health Survey Annotated Bibliography. 2nd Edition (1997), Health Assessment Lab, New England Medical Center, Boston
51. Ware J.E., Gandek B., and IQOLA-Project-Group. The SF-36 Health Survey: development and use in mental health research and the IQOLA Project. Int J Ment Health 23 (1994) 49-73
52. Ware J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
53. Ware J.E., Snow K.K., Kosinski M., and Gandek B. SF-36 Health Survey Manual and Interpretation Guide (1993), New England Medical Center, The Health Institute, Boston
54. Weissman M.M., Prusoff B.A., Thompson W.D., Harding P.S., and Myers J.K. Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis 166 (1978) 317-326
55. WHOQOL-Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28 (1998) 551-558